What is HepQuant?
HepQuant operates at the intersection of biotechnology and clinical diagnostics, providing non-invasive, blood-based quantitative assessments for liver health. The company's flagship solution, HepQuant DuO, generates a proprietary Disease Severity Index (DSI), which serves as a critical tool for clinicians and pharmaceutical researchers. By facilitating precise risk stratification and longitudinal monitoring, HepQuant addresses a significant unmet need in the management of chronic liver diseases. Their platform is engineered to support data-driven decision-making, thereby optimizing patient outcomes and streamlining the development of novel therapeutic interventions in the hepatology space.
How much funding has HepQuant raised?
HepQuant has raised a total of $341K across 2 funding rounds:
Debt
$150K
Debt
$191K
Debt (2020): $150K with participation from PPP
Debt (2021): $191K led by PPP
Key Investors in HepQuant
PPP
Public-Private Partnership
What's next for HepQuant?
With the recent infusion of capital, HepQuant is well-positioned to accelerate the adoption of its diagnostic suite across broader clinical networks. The strategic focus will likely shift toward scaling commercial operations and deepening integration with drug development pipelines, where their DSI metric provides essential insights into treatment efficacy. As the company matures, the emphasis will remain on validating the clinical utility of their non-invasive testing protocols, potentially setting a new standard for liver disease management. Future milestones will likely involve expanding their footprint in global healthcare markets and enhancing the diagnostic sensitivity of their core technology to maintain a competitive edge in the rapidly evolving precision medicine landscape.
See full HepQuant company page
